top of page
Search

Tumor Relapse and Resistance to Immunotherapy

Michelle Howard

Authors:

Amit Gutwillig, Nadine Santana-Magal, Leen Farhat-Younis, Diana Rasoulouniriana, Asaf Madi, Chen Luxenburg, Jonathan Cohen, Krishnanand Padmanabhan, Noam Shomron, Guy Shapira, Annette Gleiberman, Roma Parikh, Carmit Levy, Meora Feinmesser, Dov Hershkovitz, Valentina Zemser-Werner, Oran Zlotnik, Sanne Kroon, Wolf-Dietrich Hardt, Reno Debets, Nathan Edward Reticker-Flynn, Peleg Rider, Yaron Carmi 


Understanding The Limitations Of Immunotherapy Checkpoint Inhibition


While checkpoint inhibition Immunotherapy has been advertised as the future of Oncology, the underlying reality is that this class of interventions against cancer, suffers from many of the same systemic failures as Chemotherapy.

Notably, tumor cells can evade Immunotherapy by generating unique transient cell-in-cell structures, which are resistant to killing by both T cells and Chemotherapies.

As such, the ability of tumor cells to transiently enter and disseminate from each other in response to T-cell killing is a biological process that has never been described heretofore. It better explains how immunogenic tumors can survive in the host and provides a novel framework for Immunotherapies.




43 views1 comment

Recent Posts

See All

1 Comment


Your Blog was very much informational and is a good read. But when it is about healthcare. GD Goenka healthcare academy is the one stop solution for best paramedical courses in Bhilwara,

Rajasthan in India.

Like
The information provided on this website is for educational and research purposes only, and does not substitute for professional medical advice. You should consult your physician or health care professional to determine if any of the information is right for your unique needs.

©2024 by Hippocrates Research Foundation. Proudly created with Wix.com

bottom of page